Chengdu Easton Biopharmaceuticals Co. Ltd. has identified cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.
Cgenetech (Suzhou, China) Co. Ltd. has synthesized tyrosine-protein kinase JAK2 inhibitors reported to be useful for the treatment of autoimmune diseases, myeloproliferative diseases and graft-versus-host disease.
Pharward Biotechnology Inc. Pte Ltd. has disclosed compounds acting as E3 ubiquitin-protein ligase SIAH1 modulators reported to be useful for the treatment of cocaine dependence.
Jaguar Gene Therapy LLC’s IND application for JAG-201, a gene therapy for a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS; 22q13.3 deletion syndrome), has been cleared by the FDA.
Amphiphile (AMP)-modification of peptide antigens and molecular adjuvants has been previously demonstrated to enhance lymphatic delivery and retention, resulting in potent expansion of cognate endogenous T-cell responses.
Neutrophils are the immune system’s most abundant effector cells, which play a defensive role of host cells and clear pathogens by phagocytosis, degranulation and neutrophil extracellular trap (NET) release.
Radiation therapy resistance (radioresistance) is a key contributor to the failure of rectal cancer treatment, with immunosuppression playing a significant role here.
23andme Holding Co. has received FDA clearance of its IND application for 23ME-01473 (‘1473), a dual mechanism antibody and natural killer (NK) cell activator intended to treat cancer.
Vivet Therapeutics SAS has been awarded financing of €4.9 million (US$5.3 million) from the French government to advance the development of a gene therapy for the treatment of the neurodegenerative disease cerebrotendinous xanthomatosis (CTX).
RSS
